` Comparison: FLWR vs NOVN - Alpha Spread

FLWR
vs
NOVN

Over the past 12 months, FLWR has underperformed NOVN, delivering a return of 0% compared to the NOVN's +32% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
FLWR
NOVN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

FLWR Intrinsic Value
HIDDEN
Show
NOVN Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Flowr Corp
XTSX:FLWR
3.094 CAD
Novartis AG
SIX:NOVN
130.16 CHF
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
FLWR, NOVN

FLWR
NOVN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Flowr Corp
Revenue
Novartis AG
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
FLWR, NOVN

FLWR
NOVN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Flowr Corp
XTSX:FLWR
Novartis AG
SIX:NOVN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

FLWR
-57.3%
NOVN
75.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

Operating Margin

FLWR
-171.4%
NOVN
33.2%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

Net Margin

FLWR
-814.7%
NOVN
24.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

FCF Margin

FLWR
-91.4%
NOVN
27.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

ROE

FLWR
-225.6%
NOVN
31%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

ROA

FLWR
-103.4%
NOVN
13.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

ROIC

FLWR
-23.4%
NOVN
17.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

ROCE

FLWR
-24.4%
NOVN
23.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Flowr Corp
Novartis AG

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
FLWR, NOVN

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
FLWR, NOVN

Performance Gap Between FLWR and NOVN
HIDDEN
Show

Performance By Year
FLWR, NOVN

Loading
FLWR
NOVN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare FLWR to other stocks
LLY
Eli Lilly and Co
Cheaper
vs FLWR
JNJ
Johnson & Johnson
Cheaper
vs FLWR
ROG
Roche Holding AG
Cheaper
vs FLWR
AZN
AstraZeneca PLC
Cheaper
vs FLWR
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett